China's SFDA is no more. The agency has gotten a promotion and a new name: the China Food and Drug Administration (CDFA).
China's oversight of drug manufacturing is often faulted for being weak and ineffective and the country is often considered the capital of drug counterfeiting.
One of the big challenges of slowing the flow of counterfeit drugs is its international nature. Fakes may be made in China, for example, and make stops in several continents before finding their way into the legitimate supply chain.
China, considered a key global source of counterfeit drugs, has picked up a new partner in its fight to tame that problem.
The idea of creating a national track and trace system for the pharmaceutical supply chain is apparently alive and kicking around Congress.
Federal authorities have brought down a pawn but are still looking for the king of an extensive Chinese drug counterfeiting operation who slipped through their fingers last year.
In another major display of action, 18,000 Chinese police officers executed the roundup of nearly 2,000 drug counterfeiting suspects and destroyed 1,100 production plants.
Despite increasing reports of drug counterfeiting, track and trace programs designed to help attack the problem continue to have problems getting off the ground in the face of industry opposition.
FDA Commissioner Margaret Hamburg called on drugmakers to be "accountable for the integrity of their supply chains" to help fight counterfeit drugs.
While publicity has focused on the counterfeit Avastin recently discovered in the U.S., the problem of fakes is much more widespread than the pubic realizes. Pfizer CEO Ian Read said the company confirmed more than 50 fakes of its drugs in at least 101 countries just last year.